RAM-589.555 a new Polymerase-1 inhibitor as innovative targeted-treatment for multiple sclerosis
Graphical abstract.
Introduction
Benign multiple sclerosis (MS) signifies a sub-group of non-active MS patients, in whom in spite of the ongoing disease process patients are protected from long-term disability. Patients with benign MS reflect the capacity to withstand the deteriorating processes of the disease and the ability to endure or recover quickly from the acute demyelinating inflammatory insults. Thus, these patients are not harmed by the ongoing pathologic processes of myelin and neuronal loss that characterize active MS (Gauthier et al., 2009, Glad et al., 2009, Hawkins and McDonnell, 1999, Pittock and Rodriguez, 2008, Poser et al., 1979, Ramsaransing and De Keyser, 2007). Recently, using high throughput peripheral blood gene expression microarray analysis we identified a specific signature that characterizes benign MS (Achiron et al., 2012). This signature is portrayed by decreased expression of RNA Polymerase-1 (POL1) molecular pathway, important for ribosome biogenesis, modulation of cellular stress response and regulation of autoimmune response (Goodfellow and Zomerdijk, 2013, Leary and Huang, 2001, Quin et al., 2014, Sciascia et al., 2007, Stetler et al., 1992).
We have shown that POL1 related genes, RNA Polymerase-1 transcription factor 3 (RRN3), leucine-rich PPR motif containing protein (LRPPRC) and polymerase (RNA)-1 polypeptide D (POLR1D), play a key role in the regulation of apoptosis in MS and their decreased expression is associated with suppression of inflammation by down regulation of NFkB and activation of p53 dependent apoptosis. Moreover, in a previous study (Achiron et al., 2007) we have shown that POL1 related gene RRN3 was the leading gene that predicted good clinical outcome of relapsing-remitting MS patients over a period of two years and appropriately classified 70.4% of the patients. We have further demonstrated that blocking RRN3 expression by siRNA-silencing in PBMC cultures obtained from of RRMS patients resulted in significant increase in apoptosis confirming that signaling through POL1 pathway plays a key role in regulating cell survival in MS (Achiron et al., 2013).
Taken together, our findings provide a basis for direct targeting of POL1 pathway as an innovative strategy for selective induction of apoptosis in active MS. Moreover, the suppression of POL1 pathway can be easily monitored using the platform of POL1 related genes to validate treatment efficacy. As a proof of concept, we have recently reported that a prototype POL1-inhibitor - CX-5461 (developed by Cylene Pharmaceuticals; (Drygin et al., 2014, Drygin et al., 2010, Woods et al., 2015) delayed the appearance and significantly suppressed experimental autoimmune encephalomyelitis (EAE) in mice (Achiron et al., 2013). However, the promising potential of CX-5461 is limited for therapeutic application in MS due to a narrow therapeutic window between the minimal effective and the toxic doses. Hence, we have designed and synthesized a new POL1 inhibitor RAM-589.555. We hereby report its molecular structure, specificity to POL1 pathway inhibition, and efficacy in-vitro and in the EAE animal model. This orally administered small molecule can specifically block ribosomal RNA transcription and selectively induce apoptosis in encephalitogenic cells.
Section snippets
Newly designed and synthesized POL1-inhibitor
The newly designed POL1 inhibitor RAM-589.555 is a derivate of POL1 inhibitor CX-5461 (Fig. 1). CX-5461 was synthesized according to previously published procedures (Haddach et al., 2012). CX-5461 (100 mg (0.194 mmol)) was refluxed in 5 ml phosphoryl chloride for 2 h to generate the chlorinated analog. Thereafter, phosphoryl chloride was removed by evaporation and the crude product was suspended in 3 ml ethanol. Aniline (1 ml (0.01 mmol)) was then added and the resulting suspension was stirred at RT
RAM-589.555 reduces viability and proliferation of mice SPCs in vitro in dose dependent manner
Incubation of mice SPCs with RAM-589.555 at the following concentrations 25, 50, 100, 200 and 400 nM significantly decreased cell viability in a dose dependent manner as compared with untreated cultures (Fig. 2A). This reduced cell viability was associated with significant dose dependent decreased proliferation of SPCs (Fig. 2B).
In addition, incubation with RAM-589.555 significantly suppressed the expression of POL1 pathway key gene pre-rRNA, as demonstrated in Fig. 2C. The expression levels of
Discussion
Here we describe a new small molecule, RAM-589.555, specifically designed to inhibit rRNA synthesis based on the backbone of the prototype POL1 inhibitor CX-5461. This compound was designed by undertaking a change in Structure Activity Relationship which was solely focused on the carbonyl moiety in the prototype compound and thereby overcomes the narrow therapeutic window of CX-5461. We modified the reactivity of the carbonyl position by introducing alkyl/aryl amine. After extensive testing of
Acknowledgments
This research was supported by Israel Ministry of Trade and Industry - Nofar – Industry Program N° 51819.
References (22)
- et al.
Polymerase I pathway inhibitor ameliorates experimental autoimmune encephalomyelitis
J. Neuroimmunol.
(2013) - et al.
Targeting the nucleolus for cancer-specific activation of p53
Drug Discov. Today
(2014) - et al.
Regulation of ribosome biogenesis within the nucleolus
FEBS Lett.
(2001) - et al.
Clinical data and the identification of special forms of multiple sclerosis in 1271 cases studied with a standardized documentation system
J. Neurol. Sci.
(1979) - et al.
Targeting the nucleolus for cancer intervention
Biochim. Biophys. Acta
(2014) - et al.
The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy
Biochim. Biophys. Acta
(2015) - et al.
Impaired expression of peripheral blood apoptotic-related gene transcripts in acute multiple sclerosis relapse
Ann. N. Y. Acad. Sci.
(2007) - et al.
Suppressed RNA-polymerase 1 pathway is associated with benign multiple sclerosis
PLoS One
(2012) - et al.
The RNA polymerase I transcription machinery: an emerging target for the treatment of cancer
Annu. Rev. Pharmacol. Toxicol.
(2010) - et al.
Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth
Cancer Res.
(2011)
Rate of brain atrophy in benign vs early multiple sclerosis
Arch. Neurol.
Cited by (5)
Identification of Novel Key Genes and Pathways in Multiple Sclerosis Based on Weighted Gene Coexpression Network Analysis and Long Noncoding RNA-Associated Competing Endogenous RNA Network
2022, Oxidative Medicine and Cellular LongevityRAM-589.555 favors neuroprotective and anti-inflammatory profile of CNS-resident glial cells in acute relapse EAE affected mice
2020, Journal of NeuroinflammationNew Roles for the Nucleolus in Health and Disease
2018, BioEssays
- 1
equal contribution